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Abstract
Accurate diagnosis of traumatic brain injury (TBI) is critical to effective management and intervention, but can be challenging
in patients with mild TBI. A substantial number of studies have reported the use of circulating biomarkers as signatures
for TBI, capable of improving diagnostic accuracy and clinical decision making beyond current practice standards.
We performed a systematic review and meta-analysis to comprehensively and critically evaluate the existing body of
evidence for the use of blood protein biomarkers (S100 calcium binding protein B [S100B], glial fibrillary acidic protein
[GFAP], neuron specific enolase [NSE], ubiquitin C-terminal hydrolase-L1 [UCH-L1]. tau, and neurofilament proteins)
for diagnosis of intracranial lesions on CT following mild TBI. Effects of potential confounding factors and differential
diagnostic performance of the included markers were explored. Further, appropriateness of study design, analysis, quality,
and demonstration of clinical utility were assessed. Studies published up to October 2016 were identified through a
MEDLINE, Embase, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) search. Following
screening of the identified articles, 26 were selected as relevant. We found that measurement of S100B can help informed
decision making in the emergency department, possibly reducing resource use; however, there is insufficient evidence that
any of the other markers is ready for clinical application. Our work pointed out serious problems in the design, analysis,
and reporting of many of the studies, and identified substantial heterogeneity and research gaps. These findings emphasize
the importance of methodologically rigorous studies focused on a biomarker’s intended use, and defining standardized,
validated, and reproducible approaches. The living nature of this systematic review, which will summarize key updated
information as it becomes available, can inform and guide future implementation of biomarkers in the clinical arena.
Keywords: biomarkers; diagnosis; living systematic review; meta-analysis; TBI
Editor’s Note: This article is published as a Living Systematic Review. All Living Systematic Reviews will be updated at approximately three-six
month intervals, with these updates published as supplementary material in the online version of the Journal of Neurotrauma (see Update).
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Introduction
Traumatic brain injury (TBI) is among the most commonneurological disorders worldwide, and globally, its incidence
continues to rise.1,2 According to the Centers for Disease Control
(CDC) in the United States, over the past decade, rates of TBI-
related emergency department (ED) visits have increased by 70%.
Most of these TBIs are classified asmild (mTBI), posing a substantial
everyday workload. Clinical diagnosis remains a challenge, and CT
is considered the diagnostic cornerstone used in the ED to rule
out post-traumatic brain lesions and complement clinical assess-
ment of patients with a possible mTBI.3 However, it is generally
acknowledged that CT is not always available, implies patient ra-
diation exposure, and is relatively costly in terms of ED logistical
burden and healthcare expenditures because of the small proportion
of subjects (*10%) diagnosed as having actual traumatic intra-
cranial lesions.3,4
The need to manage patients with possible mTBI more effec-
tively and efficiently–to reduce unnecessary CT scans and medical
costs, while not compromising patient care and safety–has driven
the quest for sensitive blood-based markers as objective parameters
that can be easily and rapidly measured in the systemic circulation.
Identification of biomarker signatures associated with distinct
aspects of TBI pathophysiology may be also of clinical value for
a more accurate characterization and risk stratification of TBI,
thereby optimizing medical decision making and facilitating indi-
vidualized and targeted therapeutic intervention. As such, over the
past decades, a focused effort has beenmade to identify novel blood
biomarkers for TBI, and a growing number of candidates has been
described and proposed,5–8 leading to the recent incorporation of
S100B into the Scandinavian Neurotrauma Guidelines.9 None-
theless at present, the role of body fluid biomarkers in TBI is pri-
marily relegated to research studies, and the provision of high
quality evidence is paramount to meet regulatory requirements and
support their adoption and routine use in clinical practice.
Meta-analysis can exploit the quantity of data collected in sep-
arate studies and provide the statistical power to assess more pre-
cise estimates of sensitivity and specificity, to determine influence
of potential confounding factors on the biomarker diagnostic per-
formance, and to detect differences in the accuracy of different
marker tests. Hence, we conducted a systematic review and meta-
analysis to comprehensively summarize and critically evaluate the
existing body of evidence for the use of blood protein biomarkers
for diagnosis of brain injury as assessed by CT in adult patients
presenting to the ED after mild head trauma.
We focused on markers for which promising scientific evidence
of analytical and clinical validity is available and which therefore,
are likely to be rapidly transferable to clinical practice; namely,
S100 calcium binding protein B (S100B), glial fibrillary acidic
protein (GFAP), neuron specific enolase (NSE), ubiquitin C-terminal
hydrolase-L1 (UCH-L1), and tau and neurofilament proteins. As TBI
biomarker research and technological and analytical advances are
dynamic, we felt that a living systematic review–a high quality,
online review that is updated as new research becomes available10–
would best fit our purpose. The ‘‘living’’ nature of such work will
permit the potential inclusions and investigation of novel markers,
marker combinations, and more refined diagnostic time windows for
which relevant scientific literature/body of evidence will be gained.
Methods
This review is being prepared as a ‘‘living systematic review,’’
initiated in the context of the CENTER-TBI project (www.center-
tbi.eu).10–12 Following a predefined protocol registered on the
PROSPERO database (registration number CRD42016048154),
we conducted a systematic review and meta-analysis according to
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines.13
Information sources
We searched Ovid MEDLINE (1946 to October 2016), OVID
Embase (1980 to October 2016), OVID Evidence-Based Medicine
(EBM) Reviews (October 2016) and Cochrane Library (October
2016) for relevant studies. The search strategies used can be found
in the supplementary Appendix (see online supplementary material
at http://www.liebertpub.com).
For possible ongoing trials and studies, we searched the World
Health Organization (WHO) International Clinical Trials Registry
Platform (ICTRP) (searched November 2016) and Clinical-
Trials.gov registry (searched November 2016). Update searches
will be run every 3 months after publication, to identify new studies
for inclusion in this living systematic review.
Additional studies were identified by reviewing the reference
lists of published clinical trials and relevant narratives as well as
systematic reviews. Abstracts from relevant scientific meetings
were also examined, and experts in the field were consulted for any
further studies.
Citations were uploaded into a web-based systematic review
program (Covidence, Alfred Health Melbourne, Australia) (http://
www.covidence.org/).
Study selection
Two reviewers independently reviewed the title and abstract of
each citation identified by the search strategy. In the second stage,
the full text was reviewed and eligible studies selected. Any
disagreement between the two authors was resolved through
discussion, or where necessary, arbitration by a third party. Stu-
dies were included if the article met the prespecified list of eli-
gibility criteria: studies enrolling adult patients presenting to
the ED with a history of possible brain injury complying with
any authors’ definition of mTBI; report of the admission head
CT findings; at least one quantitative measurement of the cir-
culating biomarkers of interest (S100B, GFAP, NSE, UCH-L1,
tau, and neurofilament proteins) on admission; and relevant
accuracy data.
We included studies containing mixed populations; that is,
participants with moderate and severe TBI (Glasgow Coma Score
[GCS] <13) or pediatric populations. Studies were included irre-
spective of their geographic location and language of publication.
We excluded studies using non-quantitative methods to assess
biomarker concentrations (e.g., Western blot or explorative pro-
teomics). Studies with small cohorts (< 50 participants) were ex-
cluded, given the high likelihood of their being underpowered and
therefore impacting the reliability of findings.
Data extraction and assessment
of methodological quality
Two reviewers independently extracted data using a standard-
ized data abstraction form. We abstracted relevant information
related to the study design, patient characteristics (demographic
and clinical data, including indices of injury severity, presence
of extracerebral injuries and polytrauma, and CT findings) and
biomarker characteristics (concentrations, sampling time, cut-
offs, and statistical levels of diagnostic accuracy [sensitivity and
specificity]), analytical aspects of biomarker testing, and study
limitations. Details regarding the definition of mTBI and CT ab-
normality were also extracted.
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In the case of multiple studies from the same research group,
authors were contacted to ensure that there was no overlap in pa-
tient populations. We also contacted authors for clarification of
study sample, missing data, or ambiguity in the cutoffs used. If
biomarker measurements were taken at multiple time points, we
used the sample on admission for analysis.
The methodological quality of the included studies was inde-
pendently assessed by two reviewers using a modified version of
the tool for quality assessment of studies of diagnostic accuracy
included in systematic reviews (QUADAS-2),14 as recommended by
the Cochrane Collaboration. Discrepancies were resolved through
discussion or arbitration by a third reviewer.
Statistical analysis and data synthesis
The analysis includes a structured narrative synthesis. We
constructed evidentiary tables identifying the results pertinent
to diagnostic capabilities of the different biomarkers (detection
of intracranial lesions as assessed by CT) and study character-
istics for all included studies. We conducted exploratory analy-
ses by plotting estimates of sensitivity and specificity from each
study on forest plots and in receiver operating characteristic
(ROC) space.
Where adequate data were available, we performed meta-
analyses for each biomarker, to summarize data and obtain more
precise estimates of diagnostic performance. For studies with diverse
thresholds, we meta-analyzed pairs of sensitivity and specificity
using the hierarchical summary ROC (HSROC) model, which
allows for the possibility of variation in threshold between stud-
ies, and also accounts for variation among studies and any po-
tential correlation between sensitivity and specificity.15 For these
analyses, we used the NLMIXED procedure in SAS software
(version 9.4; SAS Institute 2011, Cary, NC). For studies that re-
ported data at common prespecified cutoff values, we calculated
the pooled estimates of sensitivity and specificity (clinically in-
terpretable), by undertaking a random effects bivariate regres-
sion approach.16
We explored heterogeneity through visual examination of the
forest plot and the SROC plot for each biomarker. However, as
there were insufficient studies, lack of individual data, and/or im-
portant variation across studies with simultaneous presence of
factors with potentially diverging effects on biomarker accuracy
estimates, we did not perform meta-regression (by including each
potential source of heterogeneity as a covariate in the bivariate
model) as planned.
Sensitivity analyses were performed to check the robustness of
the results. We used Cook’s distance to identify particularly in-
fluential studies, and checked for outliers using scatter plots of the
standardized predicted random effects. Then, the robustness of the
results was checked by refitting the model excluding any outliers
and very influential studies. Sensitivity analyses were also con-
ducted to investigate the impact on biomarker performance of
studies including mixed populations, bias in the selection of par-
ticipants, high prevalence of abnormal CT findings, and different
definitions of TBI as assessed by CT.
Data processing and statistical analyses were conducted using
Review Manager version 5.3 (Cochrane Collaboration, Copenha-
gen, Denmark) and STATA version 13.0 (StataCorp, Colleage
Station, TX) including the user written commands METANDI
and MIDAS.
Quality of the evidence
The Grading of Recommendations Assessment, Development,
and Evaluation (GRADE)17 approach was used to assess the overall
quality of evidence of the included biomarker tests. The results
were summarized using GRADEPro software (Version 3.2, 2008).
Results
Description of studies
Our search strategy identified a total of 7260 citations. Removal
of duplicates resulted in 5567 distinct citations, of which 90 full-
text articles were assessed for eligibility, and 26 articles3,18–42 were
included in the systematic review (Fig. 1, flow diagram of search
and eligibility results, and Table 1). Tables 2 and 3 show the main
characteristics of the included publications, and additional details
are provided in Tables S1 and S2(see online supplementary mate-
rial at http://www.liebertpub.com).
Two of the 26 included articles reported biomarker results from
the same patient cohort.34,43 All studies were published in 2000 or
later. With the exception of one study published in French,21 and
one published in Italian,24 all studies were published in English.
The total number of patients with TBI in the included studies
was 8127, ranging from 5028,37 to 156042 per study (median 170,
interquartile range 104–258). Of those, 865 had positive CT scans,
with an average prevalence of 17% (median 13%) (range 5–51%)
(Table 2). Table S2 shows the criteria used for the definition of TBI/
mTBI and positive CT scans (reference standard) in the different
studies. In nine articles, the presence of a skull fracture was con-
sidered as a traumatic CT abnormality.
The reported mean or median age of the included patients ranged
from 3238 to 83 years,39 with 10 studies including children and/or
adolescents (patient age <18years). The total subject pool was
largely male (median 63% across the studies), with the exception of
the study by Thaler and colleagues, which was 68.7% female.39
Two cohort studies included mild to severe TBI patients (GCS
3–15),29,38 and two other cohorts included mild to moderate TBI
patients (GCS 9–15).34–36,40 Six studies enrolled TBI patients with
multiple trauma and/or extracranial injuries (Table 2). Nine of the
included articles reported biomarker concentration from different
types of control cohorts, including healthy individuals, or non–
brain-injured trauma patients (See Table 3 for details).
Most of the studies defined the specific time frame from injury
to blood draw as an inclusion criterion, with the majority of the
samples collected within 6 h of injury (16 studies) and with mean
or median time ranging from 24.3min33 to 5 h (Table 3).28 In one
study, samples were collected within 12 h,31 and in two studies,
they were collected within 24 h.29,38
A single marker was evaluated in most of the studies (n= 21),
while one study simultaneously assessed three markers.40 Of the
eligible studies, 22 reported data on S100B (total number of TBI
patients 7754), 4 reported data on GFAP (total number of TBI
patients 783), 3 reported data on NSE (total number of TBI patients
314), and 2 reported data on UCH-L1 (total number of TBI patients
347). Fewer data were available for tau (one study that included
only 50 patients),28 and we found no studies evaluating neurofila-
ment proteins that met our inclusion criteria.
Methodological quality
The assessments of the methodological quality and risk of bias of
the included studies are presented in Figure 2 and Figure S1(see
online supplementary material at http://www.liebertpub.com).
Participants neither consecutively nor randomly enrolled, the use of
vague definitions of mTBI, or inclusion of an unrepresentative
spectrum of patients (pediatric population or patients with GCS
<13) may lead to incorporation bias, thus limiting the conclusions
that can be drawn by affecting the accuracy estimates and com-
promising the applicability of the results.
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In half of the studies, thresholds were not prespecified, and
ROC analyses were used to determine optimal cutoffs, likely
resulting in an overestimation of the diagnostic accuracy of
the biomarker evaluated. In addition, the inclusion of skull
fracture as a CT abnormality may cause inflation of the ac-
curacy estimates of S100B, whereas, using a brain-specific
marker as an index test may result in patients with skull frac-
tures being misclassified as false negative. Finally, in differ-
ent domains, a substantial number of studies were considered
to be at unclear risk of bias because of substandard reporting.
We investigated the effect of these factors in sensitivity and sub-
group analyses.
FIG. 1. Study flow diagram.
Table 1. Summary of the Number and Characteristics of Primary Articles Identified for Each Biomarker
Marker
No. of
studies
No. of
participants
No. of studies (%)
by no. of participants
in each study
No. of studies
by GCS
No. of
studies with
predefined
cutoff
No of
studies by
sample type
Relevant results
(Range individual
sensitivities and
specificities)
S100B 22 7754 (CT+ = 713;
CT- = 7041)
50–100 4 (18) GCS 15: 1 16 Serum 21 Sens 0.83–1.00
101–200 7 (32) GCS 14–15: 3 Plasma 1 Spec 0.12–0.77
201–500 6 (27) GCS 13–15: 15
>500 5 (23) GCS 9–15: 2
GCS 3–15: 1
GFAP 4 783 (CT+ = 198;
CT- = 595)
101–200 1 (25) GCS 9–15: 3 0 Serum 3 Sens 0.67–1.00
201–500 3 (75) GCS 3–15: 1 Plasma 1 Spec 0.00–0.89
NSE 3 314 (CT+ = 55;
CT- = 259)
50–100 1 (33) GCS 14–15: 1 0 Serum 3 Sens 0.56–1.00
101–200 2 (67) GCS 13–15: 2 Spec 0.07–0.77
UCH-L1 2 347 (CT+ = 64;
CT- = 283)
50–100 1 (50) GCS 9–15: 2 0 Serum 2 Sens 1.00
201–500 1 (50) Spec 0.21–0.39
Tau 1 50 (CT+ = 10;
CT- = 40)
50–100 1 (100) GCS 13–15: 1 0 Serum 1 Sens 0.50
Spec 0.75
GCS, Glasgow Coma Scale; S100B, S100 calcium binding protein B; GFAP, glial fibrillary acidic protein; NSE, neuron specific enolase; UCH-L1,
ubiquitin C-terminal hydrolase-L1.
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S100B
The accuracy of S100B for detecting intracranial lesions on CT
scan was evaluated in 22 studies (7754 patients).3,18–27,30–33,36–42
The individual sensitivities and the specificities were between 72%
and 100% and between 5% and 77%, respectively (Fig. 3). All but
six of the included studies used the same cutoff (0.10–0.11lg/L),
which represents the 95th percentile of a healthy reference popu-
lation and is conventionally considered to distinguish physiologi-
cal from pathophysiological serum concentrations.3 Seven studies
reported multiple cutoffs (Table 3). The summary ROC curve
showing the accuracy of S100B across all the studies, regardless the
threshold used, is presented in Figure 4.
In terms of the assays/platforms used, most of the studies (13/22)
used an automated electrochemiluminescence immunoassay
(ECLIA) on an Elecsys analyzer (Roche Diagnostics), while one
used the Cobas 6000 analyzer (Roche Diagnostics). There were four
studies conducted using an automated immunoluminometric assay
(ILMA) on a Liaison analyzer (Diasorin), and one was conducted
on LIA-mat (Sangtec 100); one study used a radioimmunoassay
(Sangtec), and one used an enzyme-linked immunosorbent assay
(ELISA) platform (Banyan Biomarkers, Inc.) (Table 3). In one
study, the analytical performance of the two automated immuno-
assays (i.e., Diasorin and Roche Diagnostics assays) was compared
and, although not interchangeable, the two methods strongly cor-
related and appeared usable in a similar manner.27
Performance of S100B at a 0.10–0.11lg/L cutoff value
To obtain clinically relevant estimates of the performance of
S100B, we pooled the results from the 16 studies using the cutoff
FIG. 2. (A) Risk of bias and applicability concerns graph. Review authors’ judgments about each domain presented as percentages
across included studies. (B) Risk of bias and applicability concerns summary. Review authors’ judgments about each domain for each
included study.
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value of 0.10–0.11lg/L. The individual sensitivities and the
specificities for each study included in this meta-analysis were
between 72% and 100% and between 5% and 77%, respectively
(Fig. 5). The following summary estimates were obtained: sen-
sitivity 96% (95% CI 92–98%), specificity 31% (95% CI 27–
36%), positive likelihood ratio 1.4 (1.3–1.5) and negative likeli-
hood ratio 0.12 (0.06–0.25). Figure 5 shows the pooled sensitivity
and specificity (the solid red spot in the middle) and the 95%
confidence and prediction regions (the inner and outer ellipses,
respectively).
There was a significant level of heterogeneity in the results,
greater for specificity than for sensitivity (Fig. 5). The value for
sensitivity was >80% in all the studies but one.41 The value for
specificity was mainly >30%; however, in the remaining studies,
the low specificity was accompanied by a very high sensitivity.
However, because of important variation across studies with si-
multaneous presence of factors (time, presence of extracranial in-
juries, mixed populations) (Fig. S2) with potentially contrasting
effects on the accuracy estimates and lack of individual data and/or
insufficient number of studies, we were unable to compare patient
characteristics and investigate the effect of the planned sources of
heterogeneity (see online supplementary material at http://www.
liebertpub.com). Poor reporting of patient and study information
also contributed to unknown sources of heterogeneity.
One study was an outlier (Zongo and colleagues).42 Exclusion
of this study made no change in sensitivity (96.3% vs 96.1%);
however, specificity increased from 31% to 33%. This could
be explained by the fact that in this study, including the greatest
number of patients, S100B levels were measured in plasma,
thus increasing the probability of false positive results (Fig. S3)
(see online supplementary material at http://www.liebertpub.
com).
To explore the effect of risk of bias in the patient selection do-
main on the summary estimates, we excluded eight studies con-
sidered at high (n= 1) or unclear (n= 7) risk of bias. The exclusion
of these studies slightly improved sensitivity (98%) (Fig. S4) (see
online supplementary material at http://www.liebertpub.com). A
sensitivity analysis was also undertaken to assess the impact of
studies containing mixed populations on our findings. We excluded
one study (Welch and colleagues),40 because the authors included
patients with moderate TBI (GCS 9–12). There was no impact on
our findings. Four studies enrolled a mixed pediatric and adult
population. Exclusion of these studies as well as those in which this
information was unclearly reported made no difference to our re-
sults (Fig. S4).
The prevalence of CT findings was relatively high (> 11%) in
seven studies. Excluding these studies resulted in a slight increase
in sensitivity and a slight decrease in specificity (98% and 29%,
respectively). Finally, eight studies considered skull fracture as a
CT abnormality. To explore the impact of the type of reference
standard on the summary estimates, we excluded these studies as
well as those in which this information was unclearly reported. The
exclusion of these studies slightly impacted sensitivity and speci-
ficity (93% and 35%, respectively) (Fig. S4).
FIG. 3. Forest plot showing individual sensitivity and specificity of circulating S100 calcium binding protein B (S100B), glial
fibrillary acidic protein (GFAP), neuron specific enolase (NSE), and ubiquitin C-terminal hydrolase-L1 (UCH-L1) for detection of
intracranial lesions on CT. Horizontal lines represent 95% confidence intervals. TP, true positive; FP, false positive; FN, false negative;
TN, true negative.
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Quality of evidence of S100B
The quality of the evidence for the use of blood S100B levels to
diagnose brain injury as assessed by CT scan in patients with mild
TBI was moderate (Fig. 6).
GFAP
Eligible studies reporting the accuracy of GFAP for detecting
intracranial lesions on CT scan comprised three cohorts with mild
to moderate TBI patients and one cohort with mild to severe TBI
FIG. 4. (A, B) Summary receiver operating characteristic (ROC) plots for S100 calcium binding protein B (S100B) and glial fibrillary
acidic protein (GFAP) for detection of CT abnormalities. (C, D) Study estimates of sensitivity and specificity with 95% confidence
intervals plotted in ROC space for neuron specific enolase (NSE), and ubiquitin C-terminal hydrolase-L1 (UCH-L1) for detection of CT
abnormalities. Each square represents an individual study; the size of the symbol is proportional to the number of patients in each study.
The hierarchical summary ROC (HSROC) model was used to estimate a summary curve using Proc NLMIXED in SAS.
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FIG. 5. Summary receiver operating characteristics plot of sensitivity and specificity of S100 calcium binding protein B (S100B) at a
0.10–0.11lg/L cutoff value for detecting intracranial lesions on CT. Each circle represents an individual study; size of the symbol
reflects the number of patients in the studies; red solid spot in the middle is summary sensitivity and specificity; inner ellipse represents
95% confidence region, and outer ellipse represents 95% prediction region.
FIG. 6. Summary of evidence for the use of blood S100 calcium binding protein B (S100B) protein concentrations (0.10–0.11lg/L
cutoff) to diagnose brain injury as assessed by CT scan in patients with mild traumatic brain injury (mTBI).
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patients (783 patients) (Figs. 2 and 3).29,34,36,40 All studies were
recent publications (2012–2016).
The individual sensitivities were between 67% and 100%,
whereas the specificities were between 0% and 89%. Sensitivities
were sufficiently homogenous, whereas specificities were clearly
heterogeneous. The thresholds used, ranging from 0 ng/mL40 to
0.6ng/mL29 were not pre-specified, and were determined from ROC
analyses. The summary ROC curve of the accuracy of GFAP across
all four studies, regardless of the threshold used, is shown in Figure 3.
The planned comparison between S100B and GFAP diagnostic
performance was not possible, because of the limited number of
studies and different spectrum of patients available for GFAP.
NSE
The accuracy of NSE for discriminating between TBI patients with
intracranial lesions on CT scanning from those without lesions was
evaluated in three studies (314 patients).33,41 Figure 2 shows a forest
plot of the individual study estimates of sensitivity and specificity. The
sensitivities were between 56% and 100%, whereas the specificities
were between 7% and 77%. The studies reported a considerable var-
iation in the threshold adopted, ranging from 9 to 14.7lg/L (Table 3).
UCH-L1
The accuracy of the initial circulating UCH-L1 levels for de-
tection of intracranial lesion on CT was evaluated in two very
recent studies (96 and 251 patients respectively)35,40 including both
mild to moderate adult TBI patients (GCS 9–15). The two studies
yielded the same sensitivity of 100% (95% CI 88–100) and spe-
cificities of 21% (95%CI 12–32) and 39% (95%CI 33–46) (Fig. 2).
They reported similar thresholds (0.029–0.04 ng/ml) and used the
same assay (Table 3).
Tau
The accuracy of circulating tau (cleaved tau [C-tau]) for diag-
nosis of CT abnormalities was evaluated only in one small study
(50 patients).28 The sensitivity was 50%, whereas the specificity
was 75%. Among the 10 patients with abnormal findings on CT
enrolled in this study, 5 (50%) had no detectable C-tau levels.
Discussion
In this systematic review, we have provided a comprehensive and
thorough examination of the literature on protein biomarker diagnostic
signatures for traumatic brain lesions to define how to best take ad-
vantage of these tests in ED daily patient care.We found that of the six
biomarkers explored, current evidence only supports the measurement
of S100B to help informed decision making in patients presenting to
the EDwith suspected intracranial lesion followingmild TBI, possibly
reducing resource use. There is as yet insufficient evidence that GFAP,
NSE, and UCH-L1 are ready for clinical application, despite their
unequivocal association with TBI. Further, tau and neurofilament
proteins were analyzed in too few studies to draw any meaningful
conclusions. Importantly, serious problems were observed in many of
the studies, ranging from unfocused design and inappropriate target
groups to biased reporting and inadequate analysis. These points are
further elaborated in the subsequent discussions.
S100B
Our findings demonstrate the clinical utility of S100B for the
intended use of allowing physicians to bemore selective in their use
of CT without compromising care of patients with mTBI. More
specifically, the 16 studies applying the same prespecified cutoff of
0.10–0.11lg/L yielded a pooled sensitivity of 96% (95% CI 92–
98%) and specificities of 31% (95% CI 27–36%). Assuming a pre-
test probability of 10%44 would mean that, overall, 100 of 1000
tested patients will have a final diagnosis of intracranial lesion. The
pooled results obtained for sensitivity and specificity would mean
that, of these, between 92 and 98 will test positive (true positives)
and 2–8 will test negative (false negatives). Of the 900 with neg-
ative CT, between 243 and 324 will test negative (true negatives)
and between 576 and 657 will test positive (false positives) (Fig. 6).
Even though this high sensitivity and excellent negative pre-
dictive value looks promising, information regarding which le-
sions could be missed and the associated consequences—if left
untreated—is particularly relevant to the broad acceptance and
adoption of S100B by the medical community. Accordingly, there
is an ongoing debate about the risk of sending home a misdiagnosed
patient with a potentially life-threatening condition such as an
epidural hemorrhage. From the available data,3,19,30,32,39,42 we
were unable to identify specific types of injury that were system-
atically missed, albeit subdural hematomas were slightly more
frequently misclassified as false negatives. We speculate that this
may be because of the brain lesion location and/or extension as
well as the pathoanotomical and neurovascular features of the
different injuries that cause an altered or delayed leakage of S100B
into the circulation. Importantly, one study30 demonstrated that
lesions requiring surgery (one subdural hematoma and one epidural
hematoma) were missed by S100B, thereby indicating that this
marker—if used alone as a diagnostic tool—is not completely re-
liable. Given that distinct patterns of injury are linked to patient-
specific variability, efforts must to be made to develop advanced
multiparameter-based solutions integrating marker signature and
patient features. Such multimodal prediction models could be more
suitable for an accurate diagnosis, characterization of injury types,
and risk stratification of mTBI patients.45
It will be also critical to estimate the independent and comple-
mentary value of biomarkers and determine whether this strategy
provides added diagnostic utility when combined with a careful
clinical assessment or when integrated into existing clinical deci-
sion rules for the selective use of CT, such as the CT in Head Injury
Patients (CHIP) model,46 the New Orleans criteria,4 or the Cana-
dian Head CT rule.47 Unless a biomarker-based approach yields
an incremental diagnostic value and clearly demonstrates its su-
periority over standard, readily available patient characteristics, the
broad acceptance in medical practice is unlikely.48
Reliability and reproducibility of S100B results also requires a
critical consideration of the comparability and potential variability
in biomarker measurements when using assays from different
manufacturers. We found the adoption of a relatively uniform and
standardized approach for S100B determination, with 14 studies
using the ECLIA Elecsys Roche and 2 studies using the ILMA
LIA-mat Sangtec 100. These two automated immunometric assays
have been demonstrated to have a good correlation, with almost
identical diagnostic capability,27 therefore excluding that this fac-
tor could have influenced our conclusions. A comparable level of
consistency in analytical methods and assays used is not available
for any of the other biomarkers considered in this review.
Our review showed that the results across S100B studies using
the prespecified cutoff were consistent in terms of sensitivities and
specificities, with only one outlier showing an exceptionally low
specificity (12%).42 A plausible explanation for this anomaly is that
in this study, plasma samples were used to measure S100B. This
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interpretation fits well with evidence from previous literature
demonstrating how the interference of the anticoagulant on the
immunoreactivity for S100B can alter its levels relative to serum
(values higher by*20%).49 Consequently, in the study of Zongo
and colleagues, the use of the prespecified cutoff for serum inevi-
tably resulted in a systematic increase of false positive results.42
This observation, while complicating the analysis of S100B blood
levels, points to the need for a more exhaustive knowledge and
understanding of pre-analytical factors as potential confounders
and sources of variability, and supports the adoption of different
cutoff values, depending on the sample type used. Intriguingly, this
observation suggests that plasma could be more suitable and pos-
sibly desirable for measuring S100B levels in mild TBI patients,
because of very low concentrations in this population. However,
even after removing the outlier, a considerable heterogeneity re-
mained, necessitating caution when interpreting analysis results.
Investigations from multiple research groups provided evidence
that a series of factors other than the brain injurymay influence levels
of biomarkers in the circulation and, therefore, the diagnostic accu-
racies. Such factors encompass biomarker characteristics such as
molecular weight; injury-specific release mechanisms and clearance
(Table S1);50,51 patient features including presence of extracranial
injuries or polytrauma, intoxication, location of the injury, and even
genetic, pre-analytical and laboratory-dependent procedures includ-
ing all steps from management of equipment to execution of assays
manufacturing processes; and post-analytical data handling.19,52–54
We were not able, however, to systematically investigate these po-
tential sources of heterogeneity, because of a substantial variation
across studies, the suboptimal reporting of patient and study infor-
mation, and the coexistence in the same study of factors with con-
trasting or controversial effects on the accuracy estimates. Taken
together, these findings demonstrate that future research must be
refined by improvements in study design as well as standards and
characterization of patient selection (See box on page 17) .
In this regard, surprisingly, we noted that to date no attempt has
been made to specifically investigate the effect of comorbidities and
sex on the diagnostic performance of S100B or any other marker.
Sex is recognized as a primary determinant of biological variability,
responsible for anatomical, neurochemical, and functional brain
connectivity differences, heavily influencing neurobiological and
neuropathophysiological response.55 It is also associated with im-
portant differences in hormones, metabolism, and the immunolog-
ical system, which in turn may interfere with the determination
of circulating TBI biomarker.56 Factoring sex into research designs
and analyses is a theme under active debate, and is considered
fundamental to rigorous and relevant biomedical research. Hence,
we emphasize that this is a critical knowledge gap for future in-
vestigation, especially in light of the mounting evidence of the
changing gender pattern caused by the shift in the TBI population
toward older age, also at risk of multiple comorbid conditions (see
Thaler and colleagues).39 Systematic reviews and meta-analyses of
individual participant data (IPD)may represent a powerful approach
to overcome some of these gaps and limitations,57 also supported by
the current initiatives to share clinical data and the establishment of
common repositories, such as the Federal Interagency Traumatic
Brain Injury Research (FITBIR) database (https://fitbir.nih.gov/).58
Clinical application of S100B implies that choosing the right
assessment time point (time between injury and sampling)59 is an
integral part of the test. Based on the results of S100B kinet-
ics studies, guidelines have specifically indicated a time window
within 39,60 to 69 h post-injury for S100B to detect intracranial
lesions. A recent study supported a 3 h window for safe rule-out of
acute intracranial lesion in clinical practice, showing that a second
blood sampling 3 h after the first one is not informative and resulted
in a non-trivial loss of sensitivity of*6% (e.g., eight patients with
positive CT would have been missed).27 We were unable to further
address this specific issue in this review because of the heteroge-
neity in study design. In addition to post-injury delays in sampling,
the delay from obtaining samples to processing and analysis, and
the storage conditions during this delay could both be important
modulators of S100B stability and assay results. Age, gender, and
comorbidities or their combination can also importantly affect the
kinetics of S100B.61 Future studies should inform whether these
variables should be considered, and what the potential influence on
biomarker results and interpretation is.
The results of our study expand and corroborate those from
previous systematic reviews and meta-analyses,62–64 and confirm
that the implementation of S100B might allow a reduction of the
number of CT scans by *30%.3 These considerations also have
broad financial implications for healthcare costs. However, none of
the studies in our review explored the cost effectiveness of the use
of biomarkers, and the few economic studies and data in the liter-
ature are controversial. An earlier study by Ruan and colleagues65
reported a limited effect of S100B on healthcare resources and a
potential economic impact only in specific clinical scenarios (i.e.,
CT scanning rate >78% or a faster turnaround time of biomarker
results of at least 96min compared with CT scan results). Con-
versely, in a more recent cost analysis conducted in a Swedish
regional hospital, the clinical use of S100B incorporated into the
Scandinavian guidelines substantially reduced healthcare costs,
especially in cases of strict adherence to management recommen-
dations (71e per patient).66 These results are not generalizable, and
must be carefully interpreted according to their specific contexts,
because of the differences across countries, healthcare systems,
hospital settings, and ensuing care patterns. To refine cost calcu-
lations, future studies should take these factors into consideration,
as well as CT overutilization and the socioeconomic costs associ-
ated with increased cancer risks from CT scans. Clear demonstra-
tion of cost saving and added benefits beyond those obtained by
current management strategies for mTBI are essential for TBI bio-
markers to be adopted and widely used by the medical community.
GFAP
Recent narrative reviews have outlined the potential of GFAP
for identifying patients with intracranial lesions after head trauma,7
but none of these used systematic review methods or meta-
analyses. In the meta-analysis reported here, we included four
studies, in which the diagnostic accuracy of GFAP reflected sen-
sitivities of 6729–100%36,40 and specificities of 040–100%.29 Al-
though promising, these results must be approached with caution,
because the studies included patients with severe and moderate TBI
not representative of the target population of the test (the median
prevalence of abnormal CT findings across the studies was 22%),
and thresholds were not prespecified, factors that may have inflated
the accuracy estimates.67 For diagnostic validation, it will be fun-
damental to establish reliable and valid thresholds. Also, GFAP
needs be tested in larger clinical studies with a focus on the
intended use.68,69 To this end, it has been argued that studies in-
vestigating the implementation of biomarker measurements in
guidelines for mTBI management—to avoid use of unnecessary
CT—should be limited to patients currently recommended for such
examination (GCS 14–15), therefore excluding patients with GCS
score of 13 for whom biomarker assessment would not add to
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clinical examination.9 As mentioned earlier, the definition of these
setting-specific characteristics is also critical for performing reli-
able cost analyses and determining the primary economic advan-
tage of using blood biomarkers as a pre-head CT screening tool.
A meaningful comparison between GFAP and S100B diag-
nostic performances was precluded by a substantial difference in
study populations. In this context, we note that TBI biomarkers
discussed in this review are usually considered individually. Fur-
ther work should more consistently explore simultaneous as-
sessment of multiple biomarkers providing the framework for
comparing the accuracy of tests that have directly been compared
in individual studies.
NSE and UCH-L1
The relative dearth of studies evaluating the diagnostic accuracy
of NSE, UCH-L1, and Tau in the ED for identifying patients with
intracranial lesions following mTBI hampered the possibility of
performing meta-analyses. The diagnostic value of NSE remains
uncertain, with studies showing remarkable variations and incon-
sistency. In contrast, the accuracy of UCH-L1 for detecting intra-
cranial lesions on CT scan was evaluated in two studies that yielded
an optimal sensitivity (100%) but modest specificities (21–39%).
Similar to GFAP, the thresholds used were not prespecified, and the
studies included patients with mild to moderate TBI (GCS 9–15).
Hence, further studies are required to confirm the reproducibility of
these findings and to determine clinical utility in daily bedside care.
Tau and neurofilament proteins
There is insufficient evidence to support the clinical validity of
initial circulating c-Tau or neurofilament protein concentrations for
the management of patients with mTBI.
Implications for research and practice:
Strengths and weakness of the review
Our current insight appreciates the complexity of the pathobi-
ology of TBI most probably requiring multifaceted, multimodal
approaches, integrating biomarkers and traditional clinical char-
acteristics to allow a more powerful and accurate characterization
and risk stratification of mTBI,45,70 a premise currently insufficiently
reflected in the literature. In addition, if the different biomarkers
do indeed reflect different pathophysiological processes51 with in-
dependent information about imaging abnormality, outcome impact,
and different diagnostic windows, it is possible that the use of a panel
of biomarkers may substantially increase the diagnostic specificity
for the end-point of interest.71,72 Unfortunately, to date, only a few
such studies are available. More data are needed to evaluate whether
amulti-marker approach based on a panel of biomarkers with distinct
time-dependent discriminatory accuracy provides a better perfor-
mance for the detection and characterization of TBI.
Further, we should be cautious in using CT as a gold standard to
judge the performance of circulating biomarkers. When compared
with MRI, there is increasing recognition that X-ray CT provides
poor sensitivity for structural lesions in TBI such as microbleeds and
diffuse axonal injury.73,74 It follows that we cannot assume that false
positivity in detection of CT-visible abnormality equates to false
positivity in detection of structural injury, because some of these
false positives may be associatedwith abnormalities onMRI or other
advanced neuroimaging, persistent post-concussive symptoms, or
long-term neurological, cognitive, and/or neuropsychiatric compli-
cations.75–78 On the other hand, these considerations suggest a
broader clinical application of a biomarker-based strategy for diag-
nosis and management of mTBI. Biomarkers could be used to pro-
vide guidance for prognostic groupings, to refine risk stratification,
and to inform and guide different management and treatment deci-
sions including indications for advanced MRI techniques (diffu-
sion tensor imaging [DTI], susceptibility weighted imaging [SWI],
functional connectivity MRI [fcMRI]), enrollment into clinical tri-
als, and closer monitoring and follow-up of mTBI patients.
From a clinical perspective, biomarkers are not useful if they do
not provide real-time decision support for diagnosis of mTBI at
the bedside in the ED. A successful approach to the rapid incor-
poration into routine patient care will be to develop an automated
multiplex point of care (POC) device, capable of providing accu-
rate measurements to the clinician at a reasonable cost and with
short turnaround times (*15–20min).52,53
The studies discussed in this review focus primarily on adult
patients. There is, however, a growing interest in using biomarkers
to optimize diagnosis and management of pediatric mTBI, because
of the high risk of TBI in children £4 years of age, the difficult
functional assessments, and the radiation exposure at a young age
with ensuing increased cancer risk.75,79,80 Future studies and sys-
tematic reviews taking current and new evidence into account are
urgently needed to elucidate the role of biomarkers and establish
their clinical utility in this special and vulnerable population.
Several potential limitations merit consideration. Patient selec-
tion is a critical aspect in reviews of test accuracy, as it can alter
the spectrum of disease and non-disease and the prevalence in the
population, strongly impacting test accuracy.67 Given the hetero-
geneous and polymorphous nature of TBI, in particular at the
milder end of the spectrum, there has been an inconsistent, some-
time controversial, definition of mTBI adopted in the included
studies. For example, focal neurological deficit has been considered
either as an inclusion or as an exclusion criterion (Table S2). This
diagnostic uncertainty may possibly have introduced different
biases. Although this is an issue that we cannot solve in this review
as we had to rely on the criteria that were listed in the included
studies; nonetheless, we were able to assess the robustness of the
findings using sensitivity analysis, which even demonstrated an
improvement in S100B performance (Fig. S4).
However, with respect to selection of patients and study design,
our group endorses the importance of methodological rigor, and
advocates the use of standardized protocols and a prespecified set
of data analysis both as a means to reduce related biases and
inadequate reporting, and as a mandatory prerequisite to ensure
successful validation and implementation of TBI diagnostic bio-
markers. Also critical consideration for sample size planning based
on assay precision, clinical significance, and regulatory consider-
ations is necessary. Involvement of regulatory bodies in driving
forward harmonization and standardization is considered essential.
A major step forward in this direction is the recently established
collaboration between researchers and the United States Food and
Drug Administration (FDA) in the context of the TBI Endpoints
Development (https://tbiendpoints.ucsf.edu/).
Further, despite the broad adoption by the scientific community
of the STARD statement (Standards for Reporting of Diagnostic
Accuracy studies),81 we found a number of studies with poor or in-
consistent reporting of important information, including patient and
specimen characteristics, assay methods, handling of missing data,
and statistical analysis methods, in addition to suboptimal descrip-
tions of study findings, which hampered our assessment of poten-
tial for bias and interpretation of the results. Our observations are
important in raising awareness of key reporting issues in many of the
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TBI diagnostic studies. The STARDdem Initiative recently proposed
an implementation of the STARD statement with guidance pertinent
to studies of cognitive disorders, which is expected to contribute to
the development of Alzheimer biomarkers.82 A similar initiative for
TBI biomarker studies could increase transparency and the quality of
information provided by such studies, enabling evaluation of internal
and external validity and, consequently, a more effective translation
and application of their findings to clinical practice.
Harmonization and standardization of biomarker assays that can
reliably quantify biomarkers with high analytical precision is crit-
ical to ensure that measurements are reproducible and consistent
across different analytical platforms and multiple laboratories.
Conclusion
Based on this review, we found that measurement of S100B can
help informed decision making in the ED with respect to the se-
lection of adults with a mTBI for CT scan, possibly safely reducing
resource use. Conversely, there is little evidence for clinical ap-
plication of GFAP, UCH-L1, NSE, tau or neurofilaments. How-
ever, much work remains to evaluate factors that may influence
biomarker levels, and a critical confrontation is required with the
implications for actual management, clinical impact, and health
economic implications. We also found serious problems in the
design, reporting, and analysis of many of the studies, emphasizing
the importance for the research community to establish methodo-
logical standards and acquire extensive high-quality data for TBI
biomarker validation. This is an essential prerequisite for drawing
firm conclusions about the performance of tests based on these
biomarkers and their clinical utility.
Finally, through the extensive and critical review of the current
TBI biomarker existing literature, and state-of-the-science discus-
sions with key opinion leaders and subject matter experts, members
of our work group collaborated to evaluate the evidence necessary
to demonstrate clinical utility of TBI biomarkers, to identify critical
gaps for advancing the field, and to lay the foundation for a ‘‘liv-
ing’’ TBI biomarker registry capable of providing an up-to-date list
and information on biomarker studies and their results (see Box).
Such a strategy, helping to foster collaboration, developing the high
levels of evidence needed to support analytical validity and clinical
utility, and improving the quality of assessments of novel candidate
biomarkers, should establish the solid ground needed for changing
biomarker research from data that informs into data that transforms,
turning knowledge into a new medical practice.
PANEL: CONSENSUS-BASED RECOMMENDATIONS TO ENHANCE ADOPTION OF DIAGNOSTIC TRAUMATIC
BRAIN INJURY BIOMARKERS IN THE CLINIC
1. Standardized Study and Analysis Protocols and Methodological Rigor
- Focus on ‘‘real-world’’ clinical questions (appropriate target populations) to optimize clinical translation effectiveness and
measure of healthcare economic implication.
- Increase transparency and quality of reporting by calling on investigators to adopt optimal/consolidated guidelines for
reporting biomarker work (http://www.stard-statement.org/).
- Reduce biases by implementing critical appraisal tools for evaluating the quality of research (http://www.quadas.org/).
- Develop internationally accepted common reference standards and reference methods to reduce the variability while per-
mitting reliability of biomarker results, reproducibility, and comparability across analytical platforms/laboratories and clinical
studies, and the establishment of general exact diagnostic cutoffs.
2. Additional Knowledge Needed to Improve Reliability in the Use of Blood Biomarkers and to Ensure
a Successful Validation and Implementation in Clinical Practice
- Assess relationships between specific types and patterns of injury and biomarker kinetics.
- Factor primary biological and clinical variables, including sex and comorbidities, into research design and analyses to
exhaustively understand their influence on biomarker pathophysiology and levels.
- Separate and systematically explore special populations (e.g., geriatric and pediatric traumatic brain injury [TBI]).
- Take a thorough investigative approach accounting for pre-analytical factors and adoption of different cutoff values and
alternative/complementary time points.
3. Exploration of Novel Opportunities and Strategies for Expanding and Informing Biomarker Clinical Research
as a Basis for Developing Multimodal Multidimensional Models to Diagnose Mild TBI
- Simultaneous assessment of multiple biomarkers to compare accuracy and evaluate the performance of multi-marker panels
for the detection and characterization of TBI.
- Sharing of clinical data and establishment of common repositories to support individual participant data meta-analyses (IPD-
MAs) for more robust development of diagnostic models tailored to specific (sub)populations or settings, and testing their
generalizability and usefulness.
- Systematic and rigorous evaluation, quantification, and demonstration of the incremental diagnostic value of TBI biomarkers
over standard, readily available patient characteristics, and existing prediction rules for the selective use of CT.
- Combination of brain injury biomarkers and patient characteristics yielding independent and incremental diagnostic infor-
mation toward a powerful multi-parameter platform to assist and enhance clinical decision making (triage for CT scanning) in
patients with mTBI at the bedside in the emergency department.
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Appendix: Search Strategy
MEDLINE (Ovid) 1946 to October Week 2 2016
1. brain injuries/
2. craniocerebral trauma/
3. head*.ti,ab.
4. brain*.ti,ab.
5. injur*.ti,ab.
6. trauma*.ti,ab.
7. 3 or 4
8. 5 or 6
9. 7 and 8
10. or/1-2,9
11. biological markers/
12. biomarker.ti,ab.
13. marker*.ti,ab.
14. biomarker*.ti,ab.
15. or/11-14
16. S-100*.ti,ab.
17. S100*.ti,ab.
18. S100 proteins.ti,ab.
19. S100 Proteins/
20. or/16-19
21. GFAP.ti,ab.
22. glial protein*.ti,ab.
23. glial fibrillary acidic protein*.ti,ab.
24. glial intermediate filament protein*.ti,ab.
25. astroprotein*.ti,ab.
26. GFA-protein*.ti,ab.
27. glial fibrillary acidic protein/
28. or/21-27
29. C-tau.ti,ab.
30. cleaved-tau.ti,ab.
31. tau protein*.ti,ab.
32. p-tau.ti,ab.
33. tau proteins/
34. or/29-33
35. NSE.ti,ab.
36. neuron specific enolase*.ti,ab.
37. gamma-enolase*.ti,ab.
38. enolase 2.ti,ab.
39. nervous system specific enolase*.ti,ab.
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40. phosphopyruvate hydratase*.ti,ab.
41. phosphopyruvate hydratase/
42. or/35-41
43. UCH-L1.ti,ab.
44. UCHL1.ti,ab.
45. ubiquitin carboxyl-terminal hydrolase L-1.ti,ab.
46. ubiquitin c-terminal hydrolase*.ti,ab.
47. ubiquitin carboxy- terminal esterase*.ti,ab.
48. ubiquitin thiolesterase*.ti,ab.
49. ubiquitin carboxyl-terminal hydrolase L-1, human.ti,ab.
50. UCHL1 protein.ti,ab.
51. ubiquitin/
52. ubiquitin thiolesterase/
53. or/43-52
54. NF-H.ti,ab.
55. NFH.ti,ab.
56. NFP-200.ti,ab.
57. NFP200.ti,ab.
58. hyperphosphorylated neurofilament*.ti,ab.
59. neurofilament protein*.ti,ab.
60. neurofilament H protein*.ti,ab.
61. neurofilament triplet protein*.ti,ab.
62. neurofilament protein H.ti,ab.
63. phosphorylated neurofilament.ti,ab.
64. neurofilament proteins/
65. or/54-64
66. blood.ti,ab.
67. serum.ti,ab.
68. plasma.ti,ab.
69. or/66-68
70. or/15,20,28,34,42,53,65
71. and/10,69-70
72. 71 not (animals/ not humans.sh.)
Embase (OVID) 1980 to 2016 Week 43
1. exp brain injury/
2. craniocerebral trauma/
3. (head* and injur*).ti,ab.
4. (brain* and injur*).ti,ab.
5. ((head* or brain*) and trauma*).ti,ab.
6. or/1-5
7. exp biological marker/
8. biomarker.ti,ab.
9. (marker* or biomarker*).ti,ab.
10. or/7-9
11. (blood or serum or plasma).ti,ab.
12. exp blood/
13. exp serum/
14. exp plasma/
15. or/11-14
16. exp prognosis/
17. prognos*.ti,ab.
18. exp diagnostic procedure/
19. diagnos*.ti,ab.
20. di.fs.
21. or/16-20
22. and/6,10,15,21
23. animal/ not human/
24. 22 not 23
Cochrane Library (searched 19 October 2016)
#1 MeSH descriptor: [brain injuries] explode all trees
#2 MeSH descriptor: [craniocerebral trauma] explode all trees
#3 (head* or brain*) and (injur* or trauma*):ti,ab,kw (word
variations have been searched)
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor: [biomarkers] explode all trees
#6 (biomarker* or marker*):ti,ab,kw (word variations have
been searched)
#7 (#5 OR #6)
#8 MeSH descriptor: [blood] explode all trees
#9 MeSH descriptor: [serum] explode all trees
#10 MeSH descriptor: [plasma] explode all trees
#11 (blood OR serum OR plasma):ti,ab,kw (word variations
have been searched)
#12 (#8 OR #9 OR #10 OR #11)
#13 (#4 AND #7 AND #12)
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